Arrowhead Pharmaceuticals (ARWR) Stock Near 52‑Week High After FDA Approval and New Alzheimer’s Trial: Latest News & Forecasts as of December 11, 2025
Arrowhead Pharmaceuticals (NASDAQ: ARWR) has quietly turned into one of 2025’s wildest biotech comeback stories. After years as a perpetually “promising” RNA interference (RNAi) platform, the company now has: The stock price has responded in full drama mode. As of